ArticleBlood advances2017
Hmga2 collaborates with
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- HMGA1 and HMGA2: epigenetic regulators in myeloproliferative neoplasms and novel platelet transcriptomic biomarkers of myelofibrosis.Leukemia · 2026Article
- Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.Blood advances · 2026Article
- PHF6 and RUNX1 mutations cooperate to accelerate leukemogenesis.Translational oncology · 2025Article
- A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms.Leukemia · 2025Article
- HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis.Leukemia · 2025Article
- HMGA2 promotes platelet-neutrophil complex formation and pulmonary tissue damage in myelodysplastic syndromes.Blood vessels, thrombosis & hemostasis · 2024Article
- Cellular carcinogenesis in preleukemic conditions:drivers and defenses.Fukushima journal of medical science · 2024Review
- Impaired Repopulating Ability ofGenes · 2023Article
- In utero origin of myelofibrosis presenting in adult monozygotic twins.Nature medicine · 2022Article
- Article
- The acidic domain of Hmga2 and the domain's linker region are critical for driving self-renewal of hematopoietic stem cell.International journal of hematology · 2022Article
- Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis.Leukemia · 2022Article
- Convergence of oncogenic cooperation at single-cell and single-gene levels drives leukemic transformation.Nature communications · 2021Article
- Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils.Nature communications · 2021Article
- Crucial role of hematopoieticHaematologica · 2021Article
- Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice.Journal of hematology & oncology · 2021Article
- The Non-Coding RNAs Inducing Drug Resistance in Ovarian Cancer: A New Perspective for Understanding Drug Resistance.Frontiers in oncology · 2021Review
- HMGA Proteins in Hematological Malignancies.Cancers · 2020Review
- LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a/HMGA2 axis.Bioscience reports · 2019Article
- Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.Blood advances · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-mobility group AT-hook 2 (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.